.
1801 financial statements
* Numbers in millions
Year |
2018 | 2019 | 2020 | TTM |
|---|---|---|---|---|
Capitalization * |
6 500 | 35 389 | 120 231 | 36 843 |
EV * |
2 766 | 33 829 | 120 162 | 120 162 |
Stock price ¤ |
19.42 | 30.05 | 88.6 | 27.15 |
Number of shares * |
335 | 1 178 | 1 357 | 1 357 |
EPS |
-17,24 | -1,46 | -0,74 | -0,74 |
Revenue * |
9 | 1 048 | 3 844 | 3 844 |
Net income * |
-5 771 | -1 720 | -998 | -998 |
Operating profit * |
-1 553 | -1 778 | -42 | -42 |
Total liabilities * |
1 918 | 2 474 | 3 055 | 3 055 |
Net debt * |
-3 733 | -1 561 | -70 | -70 |
Total assets * |
6 113 | 7 231 | 11 835 | 11 835 |
Equity * |
4 194 | 4 756 | 8 780 | 8 780 |
Cash and investments * |
4 525 | 4 695 | 8 048 | 8 048 |
Over the past 10 years, the maximum capitalization of Innovent Biologics, Inc. is 120 231, the minimum is 6 500. Maximum net income 0, Minimum net income -5 771. The maximum price of 1801 shares is 88.6, the minimum price is 19.42.
.
1801 valuation
Year |
2018 | 2019 | 2020 | TTM |
|---|---|---|---|---|
P/E |
-1,13 | -20,58 | -120,42 | -36,90 |
P/B |
1,55 | 7,44 | 13,69 | 4,20 |
P/S |
685,83 | 33,78 | 31,28 | 9,58 |
E/P |
-89% | -5% | -1% | -3% |
P/FCF |
-4,89 | -17,43 | -111,38 | -34,13 |
.
1801 profitability
Year |
2018 | 2019 | 2020 | TTM |
|---|---|---|---|---|
ROE |
-138% | -36% | -11% | |
ROA |
-95% | -24% | -8% | |
ROIC |
-29% | -29% | 0% |